Trial Profile

A Phase I, Randomized, Single-centered, Double-blinded Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Sep 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Allogeneic-adipose-derived-mesenchymal-stem-cell-therapy-AbelZeta-Pharma (Primary)
Indications Osteoarthritis
Focus Adverse reactions; Therapeutic Use
Sponsors Cellular Biomedicine Group

Most Recent Events

12 Sep 2018 Status changed from recruiting to completed.
16 Mar 2018 Results presented in a Cellular Biomedicine Group media release.
16 Mar 2018 According to a Cellular Biomedicine Group media release, 48-week clinical data was presented on March 16, 2018 at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS) conference.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com